The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.

导出 LinkOut

翻译打印收藏纠错

作者： James M,Lonie ^[1] ; Sandra,Brosda ^[1] ; Vanessa F,Bonazzi ^[1] ; Lauren G,Aoude ^[1] ; Kalpana,Patel ^[1] ; Ian,Brown ^[2] ; Sowmya,Sharma ^[3] ; Guy,Lampe ^[4] ; Venkateswar,Addala ^[5] ; Lambros T,Koufariotis ^[6] ; Scott,Wood ^[7] ; Nicola,Waddell ^[6] ; Riccardo,Dolcetti ^[6] ; Andrew P,Barbour ^[6]

作者单位： Surgical Oncology Group, Frazer Institute, The University of Queensland, Brisbane, QLD, Australia. ^[1] Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. ^[2] Envoi Specialist Pathologists, Brisbane, QLD, Australia. ^[3] Department of Pathology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. ^[4] Medlab Pathology, Sydney, NSW, Australia. ^[5] Medical Genomics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. ^[6] Department of Anatomical Pathology, Central Laboratory Pathology Queensland, Brisbane, QLD, Australia. ^[7] Translational and Clinical Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. ^[8] Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia. ^[9] Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, Australia. ^[10] Department of Surgery, Princess Alexandra Hospital, Brisbane, QLD, Australia. ^[11]

关键词 neoadjuvant therapy oesophageal adenocarcinoma survival treatment response tumour microenvironment

主题词人类(Humans);肿瘤辅助疗法(Neoadjuvant Therapy);肿瘤微环境(Tumor Microenvironment);生物标本库(Biological Specimen Banks);澳大利亚(Australia);腺癌(Adenocarcinoma);淋巴细胞, 肿瘤浸润(Lymphocytes, Tumor-Infiltrating)

DOI 10.3389/fimmu.2023.1220129

PMID 37965317

发布时间 2024-03-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交